Phenture capital: Pharma and VC skill-swap to Build-A-Bio
This article was originally published in Scrip
Big Pharma interest in accessing early-stage biotechnology is welcome news at a time when many venture capital firms are looking to invest their funds in later-stage technology. But the two increasingly are meeting in the middle, cooperating rather than competing to generate a return on investment, using complementary skill-sets to build innovative companies.
You may also be interested in...
Amgen had a good third quarter despite some COVID-19 impacts but did not shed any light on filing plans for two key late-stage programs nor provide any insight into Phase III asthma results for tezepelumab.
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
Amgen’s R&D programs are vitally important as sales of multiple blockbusters continue to drop, but one major late-stage asset had disappointing results and another key drug has an aggressive competitor.